Q2 2025 LifeMD Inc Earnings Call
Please stand by. Your program is about to begin. If you need audio assistance during today's program, please press star zero.
Good afternoon. Thank you for joining us today to discuss LifeMD's results for the second quarter ended June 30, 2025.
Joining the call today, are Justin shriber chairman and chief executive officer and Mark benison Chief Financial Officer. Following Management's prepared remarks, we will open the call for questioning and answer session. Before we begin, I would like to remind everyone that during this call. The company will make a number of 4 looking statements, which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected.
These risks and uncertainties are described in the company's 10K and 10 Q filings, and would then other filings that life MD may make with the secc from time to time for looking statements made during this, call are based on current information available to the company. As of today, August 5th, 2025.
The company assumes, no obligation to update or revise, any forward-looking statements after today's call except as required. By law, also, please note that the management will be discussing certain non-gaap Financial measures that the company believes are important in evaluating life. MD's performance details on the relationship between these non-gaap measures to the most comparable. Gaap measures and reconciliations thereof can be found in the press release issued earlier today.
Finally, I would like to remind everyone that today's call is being recorded and will be available for replay in the investor relations section of the company's website, and I'd like to turn the call over to life. In D CEO, Justin shriber. Please go ahead.
Thank you and good afternoon everyone after the market closed, we issued a news release announcing our second quarter Financial results and posted an updated corporate presentation on our website at IRL life md.com.
Life and D made tremendous progress, executing our strategic plan in the second quarter.
Our core tella Health business continues to deliver a strong, a strong performance, demonstrated by a 30% year-over-year, increase in Telehealth revenue and adjusted Eva growth of 560%.
Our weight management program continued its momentum, despite a large transition to branded glp-1 medications and our work simply business. Also continued to perform strongly generating nearly 3.7 million in adjusted Ava on a standalone basis.
As we looked at the second half of the year, we remained focused on several key strategic priorities: 1) continuing to grow our leading care-based weight management program, emphasizing patient experience and helping our patients access both branded and generic GLP-1 therapies, as well as oral NANG prescription weight loss therapies.
2 returning, our rexmd brand to double-digit growth by scaling. Our HRT peptide, prescription weight management, and personalized, Ed and hair loss treatment programs.
Has opportunities that address large underserved markets.
4. Further expanding and investing in our LifeMD Plus Membership service and marketplace to drive deeper patient engagement, enhance retention, and improve health outcomes.
And 5 executing on additional Enterprise Partnerships and collaborations designed to introduce significant new patient volume into our life MD plus and Specialty Care programs.
Our weight management business remains robust consistently attracting over 400 new patients signups per day.
Notably we've seen a significant increase in patients, accessing branded therapy options through our platform.
Given current trends and the improvements we expect to see in pricing and insurance coverage. We expect that by year end. The vast majority of new patients will be on an insurance covered glp1 therapy and affable cash base therapy or 1 of our oral prescription therapies for weight loss.
We continue to invest in improving the care platform that supports our weight management program.
This decision is validated by the fact that we are seeing a growing number of weight management. Patients, using our platform to access non-weight related, health care, services and products.
While our weight management segment did outperform our second quarter guidance plan for this segment weight management has been impacted by a higher than anticipated. Refund rate driven by patients either lacking insurance coverage for their medications or being unable to afford the out-of-pocket cost of branded Therapies.
Although this is a near-term headwind. We are actively enhancing our new patient intake process, to include, real-time benefit verification and other key improvements.
These updates are designed to significantly improve the patient experience and drive higher conversion rates onto therapy.
As part of these efforts, we are expanding access to a broader range of oral generic weight loss medications and adding LG glue tide as a covered option.
We remain highly confident in the long-term opportunity within prescription weight management. This is a large and underserved market and we believe the steps we're taking, will further strengthen our leadership position, despite the temporary challenges,
Turning directs, we experience a challenging second quarter, primarily due to temporarily elevated. Customer acquisition costs in the highly competitive, Ed Market. However, we have since adjusted, our marketing and product strategies, and early third quarter data, suggests the return to healthier customer acquisition levels.
We remain confident in Rex MD's long-term growth trajectory, especially as we continue to broaden our offerings into hormone replacement therapy, personalized compounded treatments for ED and hair loss, as well as additional men's health categories.
While these offerings are still small relative to the size of the overall. Brand early learning from these new areas have been encouraging and we believe that they have the potential to contribute meaningful growth in. Future quarters,
In the same vein, we're especially excited about life MD's ongoing platform diversification into high value clinical areas.
Our recent launch of a nationwide Behavioral Health offering focused on adult anxiety, and depression, directly addresses, significant unmet, patient needs and is highly complimentary to our existing offerings, including our recently. Launched life MD, plus Primary Care membership.
The mental health market is a large opportunity as about 23% of us, adults have a diagnosable mental health condition each year and only half of these people receive professional treatment.
That leaves an estimated 28 to 30 million adults with unmet Behavioral Health needs every single year.
Life from these platforms and Affiliated. Provider group is well, positioned to help address this enormous unmet clinical need
We expect this business line to begin scaling in Q4 and become a contributor to 2026 results.
Health program will address Critical Care. Gaps related to menopause hormone therapy and bone health areas, historically underserved and traditional Healthcare.
Currently, we operate a profitable concierge Women's Health Service through optimal human health, which we acquired in the second quarter.
We look forward to tapping into this significant Market opportunity with a more affordable and scalable program on the life and platform that is expected to be launched at the end of Q3.
We believe in the market fundamentals. Here are the compelling statistics: over 50 million women in the U.S. are aged 45 or older, with more than 30 million in pre-menopausal or post-menopausal stages.
Approximately 2 million U.S. women reach menopause annually. And by 2030, over 60 million women in the U.S. will be postmenopausal.
Adequate care for their symptoms. Additionally up to 70% of women at high risk for osteoporosis. Remain untreated representing a significant Gap in screening and intervention,
Life MD's clinical capabilities following the optimal human health. Acquisition along. With our fully integrated, tell Health platform uniquely positioned us to capture a meaningful share in this large growing and historically underserved care Market.
This program will begin scaling in the fourth quarter and we expected to be a creative to 2026 results.
Before I hand it over to Mark I want to briefly highlight our Clear Vision for long-term margin expense expansion which is fundamental to life. MD's continued growth
Conventional Healthcare is still struggles with persistent issues like repetitive paperwork, fragmented records and inefficient. Processes challenges that frustrate both patient patients and providers at life of D. We're directly addressing these pain points by thoughtfully integrating AI into every aspect of our operations. Our goal is simple, free up our providers from administrative tasks so they can focus on patient care and create a smoother, more efficient, patient experience.
By streamlining routine tasks, intelligently routing patient requests, and surfacing essential information exactly when it's needed, we are improving patient outcomes, provider productivity, and ultimately driving our overall business performance.
We're equally excited about our recently launched life, MD Plus Membership program. A premium offering designed to provide personalized. Patient care through around the clock access to licensed. Practitioners same day, prescription renewals comprehensive lab testing and numerous additional benefits.
Although life and D plus is still in its early stages. We've already seen promising traction with nearly 50 new patients signups per day,
We believe this program will be Central to deepening long-term patient, relationships, boosting retention and making preventive care, including annual Wellness visits, lab tests, and medication adherence as simple convenient and affordable as possible.
Together the Strategic integration of AI and continued investment in life. MD plus position, a strongly for sustainable profitability, and long-term growth.
with that I'll now turn the call over to our CFO Mark benathen to provide more detail on our second quarter Financial results and Outlook mark
Thank you, Justin and good afternoon. Everyone as Justin noted, our long-term Financial Outlook remains strong
Weight management though, experiencing some impact from higher refund rates from patients without coverage or for whom discounted cash. Pay pricing is still inaccessible performed ahead of guidance plan in the second quarter.
New subscribers for weight management, continue that strong levels and regularly exceeded 400 new patients signups per day.
Work simply maintains a strong bottom line performance with quarterly adjusted ebita of nearly 3.7 million on a standalone basis.
Our quarterly results were mostly impacted by temporary. Performance. Challenges impacting our rexmd business, which are largely behind us.
Looking at the numbers Consolidated Revenue, grew 23% versus a year ago period to 62.2 million tellah. Health Revenue, increased 30% to 48.6 million with Standalone adjusted e, but they're growing 560% to 3.4 million.
Work, simply adjusted, you but I grew 119% to 3.7 million.
Powerhouse, subscriber growth remains strong, with the number of active subscribers, increasing 16% year-over-year to over 29708 quarter end.
The number of work simply active subscribers contracted by 6% to 149,000 primarily due to their continued focus on acquiring higher. LTV customers to maximize profitability.
Gross margin for the second quarter was 88% of the client of 210 basis points. Versus the prior year due to a higher allocation rate of physician costs to cogs driven by higher utilization.
Gross profit was 54.5 Million. An increase of 19% from the year ago period.
Our gaap. Net loss attributable to Common stockholders for the second quarter of 2025 was 2.9 Million or a loss of 6 cents per share this Compares with The Gap. Net loss attributable, to Common stockholders for the second quarter of 2024 of 7.7 million, or a loss of 19 cents per share.
But that was a non-gaap measure. We defined as income or loss attributable to Common shareholders before various items as outlined in today's news release.
Adjusted you, but the total 7.1 million for the second quarter of 2025 as compared with 2.2 million in the year ago. Period.
Hell House adjusted. But as a non-gaap measure defined as adjusted, even though for only our tell Health business excluding work, simply this measure was 3.4 million for the second quarter of 2025 as compared to 0.5 million in the year ago. Period.
We exited the quarter with 36.2 million in cash and strengthened our balance sheet by fully repaying. Our senior Venture debt subsequent to quarter end this early, retirement of our debt will save life from the approximately 1.1 million of cumulative. Future interest payments, makes our business debt free and reflects the ongoing confidence. We have in our long-term Outlook
Turning to financial guidance. We are a revising. Our Consolidated, 2025 Revenue, guidance to be in the range of 250 million to 2555 million from 268 million, to 275 million previously,
Teller Health stands alone. Revenue guidance is now 195 million to 200 million compared with 208 million to 213 million. We're also revising our Consolidated adjusted IBA guidance to be in the range of 27 million to 29 million from 31 million to 33 million. Previously, we now expect 2025 tella Health Standalone, adjusted with the guidance to be between 14 million and 16 million compared with 21 million previously, updated adjusted with that guidance, still reflects a year-over-year increase of 89% to 116% First prior year
This wraps up our financial results. I'd now like to turn the call back over to Justin.
Thanks, Mark. Before we open up for Q&A, I'd like to quickly revisit the second quarter. While we weren't satisfied with our overall performance, we believe the short-term issues are largely behind us and remain extremely confident in Rex and D's long-term growth potential and strategic role within LifeMD's broader platforms.
the Strategic initiatives we laid out at the start of 2025 continued to deliver meaningful results across all areas of our business,
We've made tremendous strides in expanding and enhancing our comprehensive Telehealth, offerings reinforcing, our platform's capabilities and elevating patient experience at every step.
Our patient satisfaction scores remain outstanding, averaging 4.91 out of 5, validating the quality and effectiveness of our care model.
We continue to expand and diversify our weight management offering and our recent strategic expansions into Women's Health and Behavioral Health represents significant steps forward addressing large. Historically underserved patient populations with high quality virtual care.
These offerings combined with our increasingly robust life and D Plus Membership program.
Set the stage for Meaningful, patient. Retention higher engagement and lasting relationships that will drive margin expansion and overall business performance.
Looking ahead, our priorities remain clear. We will continue investing in and scaling high-value clinical areas like Behavioral and Women's Health.
Further optimize and expand our life MD plus program and leverage our fully integrated Pharmacy and insurance capabilities.
All of these efforts align with our overarching, commitment to deliver. The most patient Centric, comprehensive, and seamless, Healthcare experiences available anywhere.
Life MD is uniquely positioned to shape the future of healthcare and I'm excited about the path ahead as we continue to deliver outstanding care, strong growth, and long-term value for both our patients and shareholders.
With that. Let's now open the call to your questions, operator.
Thank you at this time. If you would like to ask a question, please press the star 1 on your telephone keypad. You may remove yourself from the Queue at any time by pressing star 2. And once again, that is star 1 to ask a question.
We'll take our first question from David Larsen with btig. Please go ahead.
Hey, this is Jenny Champs on for Dave. Um,
File look like for those members uh compared to cash pay. Thanks.
Yeah, hi Jenny. This is Justin.
so, as of as of today, we are contracted with over a hundred, um, over a hundred, um, insurance plans, across 40 States, we have just under 80 million lives under coverage
Uh, and a importantly, like, I expect as we've previously got that to double between now, and now, on the end of the year, it's still a very small percentage of the business. Um, it's really important because I think that we reach kind of a, you know, that we have extremely broad coverage. Um, before like we can really run, um, direct to Patient, um, kind of advertising for these offerings. So I I really think you're going to start to see the insurance business, um, scale considerably in 26 1, 1 thing. That's worth pointing out though is, you know, we have we have seen, you know, we have obviously submitted a claims across, um, you know, both commercial to commercial payers and the government payers like Medicare and, um, you know, the unit economics.
The unit economics here are strong and we're actually, like really, really encouraged about launching programs. Especially in areas like women's health. Also in the weight management vertical, uh, once you know we see broader coverage for glp1 medications, the unit Economics work. Um, and it it can be we can see better ltvs with insurance sponsored patients than we do with cash, pay patients. So to be clear like we're, you know, we're not, we haven't scaled it today. And so, although we've seen that with very, very small population, but the data that we've seen both, you know, from claims we've submitted, and from kind of third parties and peers that we've looked at like the unit economics can be very, very strong.
Sounds great.
then just
Any comments on your relationships with a Novo and Lily uh, we're assuming that those relationships are still strong. Thanks.
No, no comment. I mean those again the Integrations with uh, Lily, uh, Lily direct and Novo care are
you know, are, are in place, and we're continuing to see a, you know, greater number of patients access to the self-pay Branded therapies, uh, that are, you know, through those pharmacies that are available, um, through the Integrations of life and D has
Great. Thank you.
Thank you, and we'll take our next question from Sarah James with Cantor Fitzgerald. Please, go ahead.
Thank you. I was hoping you could give a little bit more color on what was going on with the Rex, customer acquisition cost. So, um,
Looking at the guide change compared to what Revenue had been running at, we're getting it was about 5% of Revenue. Is that in the ballpark of what the step-up in customer acquisition cost was for that segment? And can you explain a little bit more about how that happened? Was that pricing, or was it just...?
yeah.
You know, the sales that converted from the leads changing, thanks.
Yeah so this is Mark um no I mean in general we had it it bounced around a bit throughout the quarter we had some periods where tax were off 15th to 255 for some sequentially over the far quarter obviously we had some other periods during the quarter where you know it was 5% uh up. Uh obviously when tax go up by that amount, we're going to pull back on the amount of volume that we drive uh, through that business and you know, 1 of the initiatives that we're really working on and we're going to make, we started to make a lot of Headway on and we're going to make a lot more Headway by the end of the year, it's continuing to diversify the business which obviously gives us a lot more places to uh, repurpose that Capital. Um should you
You see, you know, temporary disruptions and sort of markets, like, what occurred, uh, in the Rex Market particularly within Ed. Um, but a lot of it was, you know, higher tax. Um, you know, competitive spending, uh, that in turn, um, you know, 12 down our volumes which in turn obviously had, uh, because the, you know, the, uh, economics would erode at some of those CS. Um, and in turn, uh, that would have an impact on both acquisition revenue and related, uh, subscription revenue from those uh subscribers.
Are going to go back to historical levels.
Yeah, I mean, look, we're we're, we've under, I don't want to get into the exact sort of competitive, uh, specifics. But we, we've essentially seen through some actions that we took, um, improvements in the Acquisitions per day that are, you know, not quite at the, uh, Q4 q1 levels, but they're very much approaching there. And they're, they're significantly closer and the tax have returned to the historical levels. Also, again, through some proactive actions that we took, they were changes in the market and we just had to readjust what we were, uh, doing um, could we have been a bit faster doing that? Yes. Um, but you know, we did adjust and I think we're in a good place now.
There, this is Justin, I'll just add, like, remember, we had this, we had a massive, we had an enormous transition, right? This this, this this past quarter with the weight management business, which just, you know, really requires a lot of energy from, you know, almost everybody in the organization. And, you know, some, some of the, you know, the, the we did see, we obviously saw these changes in the, you know, in the, in the competitive environment. But, you know, some of it was just think we, you know, we we took our eye off the ball for a little bit and, um, you know, it's we, we should have gotten this thing back online, a little quicker and we didn't. But again, as we tried to, as we communicated in the, you know, on the, on the, on the call earlier, like we we feel really good about where the business is. There's a lot of exciting kind of new product opportunities for for Rex and d. And this, you know, we really wanted to
Indicated. This isn't something that uh, you know we we're going to we think we're people should be concerned about going forward.
Okay, that's helpful. Thank you.
Thank you. And next, we're going to go to Ryan Myers with Lake Street Capital markets. Please go ahead.
Yeah guys, thanks for taking my questions. Just kind of as a follow-up to the last question. Um, just want to make sure I fully understand it. So the full year guide down that's totally related to the Dynamics faced with the Rex MD business. Despite the fact that you guys now have that resolved, just want to get an understanding of any impact that we would see from that in Q3, and then more, you know, recently in Q4. Yeah.
Yeah, so the majority of its related to that there, there's a small proportion as you mentioned in the short term, there's awesome higher refund rates on the Wade, management patients, and we're talking a few percentage points higher. Um, that was a small proportion, uh, of the changes which we've built into the Q2 and Q3 I'm sorry, the Q3, uh, guy. But the vast majority of it was the impact from performance and Rex and Q2 and then the downstream impact associated with less, uh, new subscribers that came in the door in Q2 retaining those people, uh, throughout the year. And uh, you know, slightly softer sales performance than we had. Historically. See and obviously we're we're building back, but I'd say you know, right now in terms of sales per day, um we're at about 85 to 90% of where we've been historically. Um,
Which is a big improvement over where we had been in the middle of Q2. Um, but all of that is baked into the guidance now. We've not assumed any potential, um, you know, complete rebound, uh, in Rex within that guidance. So we think we've taken a prudent, uh, point of view on that.
Okay, got it. And then just on the topic of the LifeMD, plus offering, you know, any way we should be thinking about sort of marketing, in any sort of spend that's associated with that, as that continues to become larger and you guys put more kind of emphasis on that business.
Yeah. Um, this is
All that big.
You know, as we've said, our marketing spend does tend to go up quarter on quarter, that was baked into the back half of the year. I mean, do any of these businesses require? Very significant investment. No. But you do have to uh, make the uh, initial investment and look today where bringing on about 15 new signups there, obviously, we'd like to scale that uh significantly higher but we're going to end up doing it in, you know, a measure of fashion as we do with a lot of our new launches to, you know, balance profitability with the growth of the company.
Got it. Thanks for taking my questions.
Thank you. And we'll next go to Anderson shock with B Riley Securities. Please go ahead.
Hi, thank you for taking our questions.
Uh, could you provide any color on what percentage of patients with insurance coming in for GLP-1s are being approved for coverage?
Um, we
We don't have an actual percentage, Anderson, but I mean, again, like I can emphasize that.
The uh, kind of number 1 performer. Um and then we'll go be also performing really well. And, you know, like 1 of the things that we mentioned in the script is I'm actually super confident that you know, by the end of the year.
You know, I think we'll probably see.
I think it's safe to say that we'll see, 75% of of new patients either on an insurance covered glp1 medication like Gobi or, or is that bound?
Um, or or paying, um, for 1 of the 1 of the kind of self-pay products there. So it's it's been like performing really, really well.
We're also launching we're also. We're also launching more of the kind of oral. Generic oral therapy options. So we think that that probably can be, you know,
Somewhere between at least 10% and 20% of the business, based on what we've seen with our peers in the virtual care world.
Okay, got it. That's that's helpful. And then could you provide an update on the recent launch? Uh, in Behavioral Health. I guess how many uh initial subscribers have you seen, and how should we think about Revenue contribution from this launch in the back half of the year?
Yeah I mean this is Justin again so look we you know we we've put a lot of work into getting this live it's currently live across all 50 states don't have we're not ready to release like an exact patient number. Um but we are you know we are on boarding patients on the the program every day. You know, the way these things typically work is you know over the first couple months when we launched 1, it's it's all about testing and, you know, kind of working out, not not Kinks at all. And they care but more Kinks and like the intake process and, you know, just making sure everything's working smoothly, making adjustments. And, you know, and then, and then it comes down to scale. So, I mean, we're, we're really right now. It's it's definitely not, it's not scaling per se, but um, we're really, really bullish on this. And it's, it's something that we're extremely confident, it's going to start to scale over the next 30 60 days,
Okay, got it. And then how is the
Medicare fee for service initiative progressed since April, have you been able to expand as expected, reaching 49 states and 60 million beneficiaries? At the end of the second quarter?
So we're still on track, we're still on track to to expand this to to 49 states. Um, by the end of the year, um, we had to, we had to rework, um, some structural things with the, with the Medical Group over the course of the last, like 90 days. So, you know, we haven't we we haven't started to scale the the Medicare program yet, but it's something that we expect will scale in in, you know, in the back half of this year.
Okay, got it. Thank you for taking our questions.
And we'll next go to Stephen descarte with keep keep Bank. Please go ahead.
Hey guys, thanks for the questions. Um I guess just curious on.
you know what what the refund rate policy is with your customers and then just
You know, anything that drove that to be higher in the quarter, but anything have to do with the novo or the Partnerships? Thanks,
Are you you're kind of breaking up a little bit there? Stephen can can can you sort of see the special of the I heard the first part of your question on?
On refund rate and refund policy, but what was the second 1?
Just was there any of that tied to the Denovo or Billy partnerships with those going into effect this past quarter?
Yeah sure. So I mean our our refund policy is extremely liberal, I mean if if a patient
Comes in and doesn't get treatment or you know, doesn't have insurance coverage. Um, doesn't want to pay for a cash, pay therapy. They basically get a refund, right? Um, you know, some patients will pay. I mean, technically, according to the policy like if they have a consult, they would pay they would need to pay for the consult. But in reality
If if somebody wants a refund they get a refund and they get a full refund. So that that's the policy, look, it's I don't think that certainly like the collaborations with Lily and novel have not I mean those the the the collaborations with those pharmacies
Have not like had a direct have not had a direct effect on the refund rate. But I mean what does have an effect on the refund rate? Is just the fact that for for a lot of patience, right? Like the self-paid, the self-paid drugs uh are
just getting
A $500 month, rented therapy through life MD or they can go. There's another 100 providers out there that are still offering a hundred to $150 per month. You know, compounded semaglutide or trespassed product.
Um, and we look, we, we appreciate that.
You know look the bottom line is is like there still is not a reduction in the number of competitors out there selling, you know, exact replicas of tirzepatide and semaglutide.
so that, that, as you can imagine, like,
we have a lot of patients that come in. And they, if they don't have insurance coverage, we can't submit a prior off and get them covered for a medication.
Um, many of them do request a refund and go elsewhere and find a cheaper alternative of the medication.
Okay, thanks.
Frame. And if so, you know, kind of
What roughly percentage of your weight management subscriber base is is on those? Thanks.
Um yeah. I don't I don't have a exact percentage to share you to share with you but cert certain patients the, you know that qualify um for a personalized glp1. Um,
Again like our providers are willing to send prescriptions to third-party pharmacies for personalized, glp1 medications. Um, you know, if the clinical presentation of the of the patient is is appropriate, right?
So I think we're we're very you know our providers are very conservative with this. Um but in certain situations yes our providers will send uh personalized prescriptions to third-party Pharmacy.
Okay, thank you.
Thank you. And next, we'll go to Xian with HC Winright. Please go ahead.
Hi. This is Juan for ye um I was hoping to get a little bit more color on the uh tend to get a feel for the number of subscribers that are currently using the weight management versus the tele Health active subscriber count and see what fraction of
Users uses each of those business segments.
Yeah, yeah, I mean, look we uh we we haven't historically broken it out but you know, in general all the way management. Subscriber counts as a percentage of, you know, the active is roughly kind of in that range of 30 to 35% uh, of the total. Um, and then obviously, the largest proportion is within Rex. Um,
Obviously, the average weight management customer is worth, you know, more on a one-year basis than the average customer. Um, and then you have other indications around that, uh, sleep, hair loss, and things like that.
Got it. That's, that's really helpful and do you. Are you guys open to, uh, providing any numbers on the attrition rates in each of, those kind of, to understand what retention looks like, in each of those business segments? Yeah, I I mean look what we've disclosed publicly is typically we retain about a third of cohorts after 12 months. I mean, look, we have 1, 3, 6 months some cases. We've had 12 months subscriptions. So it's, you know, we try to normalize it at 1 year, mark. But historically, we will retain about a third of the initial cohort at the end of 12 months. Obviously, in the weight management business. A big chunk of that fall off occurs and the first 30 days with, uh, refunds for people that don't actually get on therapy. Um, if you know you go by the folks that are on therapy, the retention rate is obviously much higher.
Got it, got it. And in general you mentioned a few times about, you know, your focus and prioritization of getting good insurance coverage for your patience and kind of making that into your system. Do you think that's your post meaningful differentiating feature for against other tele health?
Uh, competitors.
Sure, this is Justin, I I think that look I think that's certainly 1 of our 1 of the big differentiators with life and D is, you know, is the infrastructure for medical and and Pharmacy benefits that are that we're building. I, I think it's also, you know, our ability to operate a, you know, a high quality, um, synchronous care platform across all 50 states, you know, at the scale that we do,
um, and
And um, you know, subsidized the cost of their care and access like either again asynchronous care if it's more convenient for them or synchronous care. If they really want to speak to a doctor which will, you know and have a face-to-face visit which a lot of people do.
Um, we think that's a super unique and in fact, we know that's super unique.
Got it. Thanks for asking to answering the questions.
Thank you and that concludes our Q&A portion of the call, I will now turn the call back over to Joshua.
Thank you for your question uh and and for your interest in life. MD we look forward to speaking with you once again, when we report our third quarter results in November have a great evening,
This does conclude today's program, thank you for your participation. You may disconnect at any time.
Whom.